# Comparison of Dapagliflozin, Lobeglitazone, and Its Combination in Efficacy and Safety

> **NCT05915949** · PHASE4 · UNKNOWN · sponsor: **Seoul National University Bundang Hospital** · enrollment: 99 (estimated)

## Conditions studied

- Diabetes Type 2

## Interventions

- **DRUG:** Dapagliflozin 10mg Tab
- **DRUG:** Lobeglitazone 0.5 mg
- **DRUG:** Dapagliflozin + Lobeglitazone

## Key facts

- **NCT ID:** NCT05915949
- **Lead sponsor:** Seoul National University Bundang Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-01-01
- **Primary completion:** 2023-10-30
- **Final completion:** 2023-12-31
- **Target enrollment:** 99 (ESTIMATED)
- **Last updated:** 2023-08-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05915949

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05915949, "Comparison of Dapagliflozin, Lobeglitazone, and Its Combination in Efficacy and Safety". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05915949. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*